Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...

Shares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...

As Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...

We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...

对于患者而言，FDA 泄密使其难以准确判断药物安全性与有效性，在治疗选择上陷入迷茫。药企则因泄密面临市场波动与决策困境，研发进程受阻。整个医药行业呼吁 FDA 尽快采取措施，解决泄密问题，恢复监管公正性与透明度，确保药物审批流程的科学性与严谨性，为患者和药企营造稳定、可信赖的监管环境。否则，FDA 的公信力危机将持续发酵，对美国乃至全球医药行业创新与发展产生不利影响。

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Dr Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene therapy and pressure from the White House. He plans to return to California to ...

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The Independent ...

The president overruled his HHS secretary and FDA chief, four people with knowledge of the decision tell POLITICO.

The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...